Illumina Inc. has announced a definitive agreement to acquire SomaLogic, a leading provider of data-driven proteomics technology. This acquisition is set to enhance Illumina's presence in the expanding proteomics market and support its multi-omics strategy. The move underscores the value of Illumina's NovaSeq X series as a key facilitator for next-generation multi-omics applications. Until the transaction is completed, Illumina and SomaLogic will continue to operate as separate entities.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Illumina Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: GE64103) on September 07, 2025, and is solely responsible for the information contained therein.